Weill David 4

What Happened

• David Weill, a director of TransMedics Group, Inc. (TMDX), received a grant of 2,922 restricted stock units (RSUs) on 2026-05-20. The reported acquisition price is $0.00 per RSU, resulting in $0 cash outlay on the Form 4 filing.
• This transaction is an award/grant (transaction code A) — not an open-market purchase or sale. RSUs are a contingent right to receive shares upon vesting, so they do not represent immediately owned common stock.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-22 (timely within the 2-business-day filing window).
• Amount: 2,922 RSUs; reported acquisition price: $0.00; total immediate cash value reported: $0.
• Shares owned after transaction: not specified in the supplied filing details.
• Footnote: Consists of 2,922 restricted stock units. Each RSU represents a contingent right to receive one share of common stock (vesting conditions may apply).

Context

• RSU grants are typically compensation and vest over time per plan terms; they are not the same as an outright market purchase and do not necessarily signal buying pressure.
• No sale, purchase, exercise, or 10% ownership change is indicated in this filing.